

Applicants: Ira Tabas
Serial No.: 10/767,749
Filed: January 28, 2004
Page 2

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1. (currently amended) A method for inhibiting macrophage death in a subject having, or at increased risk for developing, cardiovascular disease which comprises administering to the subject an amount of an amphipathic amine or a pharmaceutically acceptable salt thereof effective to inhibit the intracellular transport of cholesterol within macrophage cells from an intracellular cholesterol storage site to the endoplasmic reticulum but not to the plasma membrane, so as to thereby inhibit macrophage death in the subject.
2. (currently amended) A method for inhibiting atherosclerotic lesional complications in a subject having, or at increased risk for developing, cardiovascular disease which comprises administering to the subject an amount of an amphipathic amine or a pharmaceutically acceptable salt thereof effective to inhibit the intracellular transport of cholesterol within macrophage cells from an intracellular cholesterol storage site to the endoplasmic reticulum but not to the plasma membrane, so as to thereby inhibit atherosclerotic lesional complications in the subject.
3. - 26. (canceled)
27. (currently amended) A method for inhibiting atherosclerotic lesional necrosis or plaque rupture in a subject having, or at increased risk for developing, cardiovascular disease which comprises administering to the subject an amount of an amphipathic amine or a pharmaceutically acceptable salt thereof effective to inhibit the intracellular transport of cholesterol within macrophage cells from an intracellular cholesterol storage site to the endoplasmic reticulum but not to the plasma membrane, so as to thereby inhibit atherosclerotic lesional necrosis or

Applicants: Ira Tabas
Serial No.: 10/767,749
Filed: January 28, 2004
Page 3

plaque rupture in the subject.

28.-49. (canceled)

50. (previously presented) The method of claim 1, wherein the amphipathic amine is 2β -(2-diethylaminoethoxy)-androsteneone (U18666A).

51. - 52. (canceled)

53. (previously presented) The method of claim 2, wherein the amphipathic amine is 2β -(2-diethylaminoethoxy)-androsteneone (U18666A).

54. - 61. (canceled)

62. (previously presented) The method of claim 27, wherein the amphipathic amine is 2β -(2-diethylaminoethoxy)-androsteneone (U18666A).

63. - 64. (canceled)

65. (withdrawn) The method of claim 1, wherein the amphipathic amine is imipramine.

66. (withdrawn) The method of claim 2, wherein the amphipathic amine is imipramine.

67. (withdrawn) The method of claim 27, wherein the amphipathic amine is imipramine.

C